Hypertrophic cardiomyopathy (HCM) is defined as primary hypertrophy of the
heart muscle, usually the left ventricle which is not dilated. HCM is a rel
atively common disease with a prevalence estimated at about 1 in 500. It is
a complex disease with relatively stereotypical anatomical features but a
very variable clinical presentation with a major risk of complication. All
forms may be observed from almost asymptomatic hypertrophy to severe famili
al forms with multiple cases of sudden death. Over the last few years, mole
cular studies of the genetic abnormalities responsible for HCM have improve
d our understanding of the clinical variability of this disease.
Schematically, HCM is caused by mutation of one of 4 genes which code the p
roteins of the sarcomere : the gene of the heavy chain of beta-myosin, the
gene of cardiac T-troponin, the gene of alpha-tropomyosin and the gene of p
rotein C linked to cardiac myosin. The main problem for clinicians is not m
aking the diagnosis, which is relatively simple by echocardiography, but to
assess the risk of complications, especially in adolescents and young adul
ts, Patients over 40 to 45 years of age pose fewer problems as their diseas
e is generally associated with a better prognosis since they have already s
urvived to that age. There are many prognostic factors of sudden death, a r
eflection of the multifactorial character of sudden death in this disease.
Four major risk factors have been identified : a family history of sudden d
eath, abnormal blood pressure changes on exercise, a history of syncope and
non-sustained ventricular tachycardia on 24 or 48-hour Holter monitoring.
In children and adolescents, only the first three factors may be used, know
ing that syncope, though rare, carries a very poor,prognosis. On the other
hand, in adults up to 40, all 4 factors are valid. Unfortunately their posi
tive predictive value is relatively poor, all the patients with one of thes
e risk factors not automatically experiencing sudden death. On the other ha
nd, their negative predictive value is excellent. Therefore, a patient with
none of these factors has an excellent prognosis and should be allowed to
lead a normal life. The risk is considered to be high when 2 or 3 of the fa
ctors are associated, theoretically justifying aggressive management (amiod
arone ? defibrillator ?). Finally, there is no established management proto
col in cases with a single risk factor. The discovery of mutations causing
HCM will probably open up new methods of assessing the risk of sudden death
in this disease. It would seem to be, possible to assess the impact of the
genotype on prognosis. However, this "genetic stratiftcation" remains the
realm of top research teams and is not yet accessible routinely in clinical
practice.